Drug intelligence / Profile preview

BDB018

Development stage: Phase 1
Lead developer: Seven and Eight Biopharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

BDB018 is a next-generation, intravenously administered small molecule immunotherapy that acts as a dual agonist of toll-like receptor 7 and 8 (TLR7/8). It was specifically designed to further enhance immune activation against cancer while maintaining a favorable safety profile similar to its analogue, BDB001. By binding to and activating TLR7 and TLR8 on immune cells, BDB018 stimulates innate immune pathways leading to antitumor activity. The drug is being developed for the treatment of advanced solid tumors that have relapsed or are refractory to standard treatments. Clinical development includes monotherapy as well as combination therapy with pembrolizumab in unresectable or metastatic solid tumors[1][4][5][7].

Targets

TLR8 (Toll-like receptor 8)TLR7 (Toll-like receptor 7)

Beyond the preview

Go deeper on BDB018.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BDB018.

Explore the full profile